Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.

Related Articles

Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.

Gynecol Endocrinol. 2013 Jun 14;

Authors: Gadducci A, Sergiampietri C, Guiggi I

Abstract
Abstract The limited efficacy of endocrine therapy and chemotherapy has stimulated several researches aimed to detect novel molecularly target therapies for advanced, persistent or recurrent endometrial cancer. Prior attempts to block vascular endothelial growth factor (VEGF) with sunitinib, sorafenib and thalidomide have obtained disappointing results. Bevacizumab has shown a promising activity in a phase II study. The percentages of patients with progression-free survival ?6 months were similar for endometrioid (35%) and serous carcinoma (36%), but the number of cases was too small to assess the relevance of histological type for response to bevacizumab. In a phase II study, aflibercept was administered every 2 weeks to women with recurrent or persistent disease after chemotherapy. Forty-one percent of the patients were progression-free at 6 months, but 32% of the women had been removed from study because of toxicity. The detection of activating mutations of Fibroblast Growth Factor Receptor (FGFR)-2 in primary endometrial carcinoma has generated a new avenue for the development of molecularly target agents. Dovitinib, a tyrosine kinase inhibitor targeting both VEGF receptor (VEGFR) and FGFRs, is under clinical investigation in different malignancies including endometrial cancer.

PMID: 23767831 [PubMed - as supplied by publisher]

AKT Inhibitors selleck chemicals reversible Akt inhibitor akt2 inhibitor